Clinical Trials Directory

Trials / Sponsors / Avistone Biotechnology Co., Ltd.

Avistone Biotechnology Co., Ltd.

Industry · 11 registered clinical trials — 9 currently recruiting.

StatusTrialPhaseStarted
RecruitingAndamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients Wi
Non-Small-Cell Lung Cancer
Phase 22026-03-11
Not Yet RecruitingVebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Adva
Non-Small-Cell Lung Cancer
Phase 32025-05-15
RecruitingA Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Phase 12025-03-06
RecruitingVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastati
Non-Small-Cell Lung Cancer
Phase 22024-08-07
RecruitingA Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Phase 12024-07-08
RecruitingA Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Phase 12024-06-24
Active Not RecruitingA Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Phase 12024-05-19
Enrolling By InvitationEfficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion
Non-Small-Cell Lung Cancer
Phase 32023-12-01
RecruitingA Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced a
Non-Small-Cell Lung Cancer
Phase 22023-07-21
RecruitingVebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Followin
Non-Small-Cell Lung Cancer
Phase 1 / Phase 22023-06-13
UnknownAssessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Phase 12020-08-25